During the event, Antengene will review promising data of its R&D pipeline, including The virtual English session to be held at 8:30 AM, November 17, 2023, Eastern Time / 9:30 PM, Beijing Time.
The hybrid Chinese session to be held in Shanghai at 8:30 AM, November 17, 2023, Beijing Time.
"Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will host its 2023 R&D Day on November 17, 2023, to update the medical and investor communities on the company's progress with its R&D programs. The session will feature three KOL sessions, and discussions about the data of Antengene's key drugs in clinical development, including ATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitorCD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor); and updates on its proprietary R&D pipeline and upcoming development for 2024. Three guest experts will participate in the presentations and discussions at the event, they are:
Dr. Adnan Khattak, M.D., Ph.D (One Clinical Research, Australia) who will discuss CD73 inhibitors; Dr. Anthony J. Olszanski, M.D., RPh(Fox Chase Cancer CenterCancer Center, the United States) who will discuss tumor immunotherapy, including targeting the PD-L1/4-1BB pathways; and Jay Mei, M.D., Ph.D. – Founder, Chairman, and CEO
Amily Zhang, M.D. – Chief Medical Officer
Bo Shan, Ph.D. – Chief Scientific Officer
Godfrey Guo, M.D. – Executive Director, Clinical Development
Bing Hou, Ph.D. – Executive Director, Drug Discovery
A live question and answer session will follow the presentation.
The virtual event will be held in English at 8:30 AM, November 17, 2023, Eastern Time/ 9:30 PM, Beijing Time.
To attend the session, please register at https://event.webcasts.com/starthere.jsp?ei=1641243&tp_key=6683586ef4.
For participants in the Mainland of China, please register at https://event.cnwebcasts.cn/starthere.jsp?ei=1641243&tp_key=6683586ef4
A Hybrid Chinese session will also be held in-person at the Antengene Shanghai Office and virtually at 8:30 AM, November 17, 2023, Beijing Time. To attend the event virtually, please register at https://s.comein.cn/Af755.
For in-person attendance, please register at https://s.comein.cn/Af75u or contact Antengene's Investor Relations Team at [email protected]. About Adnan Khattak, M.D., Ph.D
About Anthony J. Olszanski, M.D., RPh
Anthony J. Olszanski, M.D., RPh is the Vice Chair of Clinical Research; Director of the Early Clinical Drug Development Phase I-III Program; and Co-Director of the Cutaneous Oncology Program with specialty in melanoma, at the Fox Chase Cancer Center (Fox Chase). Dr. Olszanski has led over 70 trials and is dedicated to helping patients in the treatment of lung cancer and cutaneous malignancies, with a focus on melanoma. He sits on the NCCN panels on Melanoma and the Management of Immunotherapy-Related Toxicities. Dr. Olszanski received his medical training at the University of Medicine and Dentistry of New Jersey, completed his internal medicine residency and fellowships in Oncology/Hematology and Clinical Pharmacology Fellowship at the Geisel School of Medicine at Dartmouth. Dr. Olszanski is board certified in Medical Oncology and Clinical Pharmacology. About Shehara Mendis, M.D., M.S.
Shehara Mendis, M.D., M.S., is a medical oncologist at Cabrini Health, Melbourne, Australia, with a focus in gastrointestinal cancers. Dr. Mendis received her medical and specialty training in Melbourne, Australia, and then obtained a Master of Cancer Sciences while undertaking a clinical and research fellowship specializing in cancers of the gastrointestinal tract at BC Cancer in Vancouver, Canada. Since her return from Canada in 2019, Dr. Mendis has held appointments at Western Health and Cabrini Health. She also holds clinical research appointments at the Walter & Eliza Hall Institute (WEHI), Melbourne Health, and Monash University. "Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia. Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange.
For more information, please contact:
E-mail: [email protected]
E-mail: [email protected]